Report me for selling fake medicine? Why are you crying when your illness relapses?

……

"1000 billion? He actually wants 1000 billion?"

"Is Chen Xuan crazy? How dare you even mention such a price?"

"No wonder AbbVie's acquisition failed. No pharmaceutical company in the world could possibly offer that price."

After receiving this news,

Qin Guoming was shocked and even a little out of control.

The amount of 1000 billion really left him stunned.

If he hadn't seen the interview video with his own eyes, he would never have believed it was true.

If Chen Xuan hadn't said it himself, he would have thought it was a fabrication by marketing accounts and self-media.

At this moment, he finally understood why Abovi gave up directly.

Faced with such a huge demand of 1000 billion, even AbbVie, with its strong financial resources, can only sigh in despair.

In Qin Guoming's opinion, no pharmaceutical company in the world would agree to such a sky-high acquisition price.

You know, 1000 billion yuan is equivalent to most of the market value of Changfeng Group. How could he possibly pay it out?

For this kind of project, let’s not talk about whether we have the ability to win it.

Even if it can be taken down, the group's capital chain will be in crisis.

If any accident happens, the skyscraper will collapse instantly.

So, he simply chose to give up.

Faced with the 1000 billion offer, he was shocked.

But after hearing what Chen Xuan said next, he couldn't help but have other thoughts.

"Is Chen Xuan developing new drugs again?"

"How did he do this? Or was there a top-notch laboratory helping him?"

"But what field is this new drug in? Will it be another effective cancer treatment? If it's successful, will he sell the patent this time?"

Lighting a cigar, Qin Guoming looked out the window with a deep gaze, a gleam in his eyes.

He was originally planning to leave Jiujiang directly.

But after hearing that Chen Xuan had developed a new drug, he immediately changed his mind.

At the same time, I feel extremely unbalanced.

Changfeng Group has tried to develop new drugs before, and it is also jealous of the market for original drugs, which often have sales of tens of billions or even hundreds of billions of dollars.

In fact, he did take several actions, but the result was failure without exception.

There is no way. The investment in researching and developing new drugs is really too scary. The consumption of various human, material and financial resources is terrifying. It is a pure money-burning behavior.

Moreover, it is not only very expensive, but also very time-consuming. Even if you invest all your money, you may not get any results even after several years.

For many best-selling drugs, the time from their initial launch to final approval for marketing is extremely long.

This is not just about establishing the top at the beginning. Even from clinical trials to approval for marketing, the average time in China is as long as five years, and the situation is similar in foreign countries.

Even if you succeed by chance and get approval for listing, you won’t be able to make money right from the start.

The sales of some drugs are very low in the first few years, and it will take several years of operation before sales increase.

In other words, the birth of every innovative drug has to go through countless risks, and each risk may end in failure.

Therefore, even if Qin Guomin is not coveting the profits of innovative drugs, he will have to give up every time because he burns too much money.

Whether it is the money burned or the time required, it is difficult for a businessman like him to persist.

Because of this, even though Changfeng Group is considered one of the leaders in China's pharmaceutical industry, it still focuses on making quick money and rarely develops innovative drugs.

The annual marketing expenses far exceed the R&D investment, so how can we develop any innovative drugs?

But it was precisely because Changfeng Group could not get it that Chen Xuan achieved success repeatedly.

The achievements of two world-class innovative drugs are not enough, and now new drug achievements have been born.